BTTA.Y Stock Overview
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Biotest Aktiengesellschaft Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €24.27 |
| 52 Week High | €24.27 |
| 52 Week Low | €24.27 |
| Beta | 0.43 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 0% |
Recent News & Updates
Recent updates
Shareholder Returns
| BTTA.Y | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 1.5% | 1.2% |
| 1Y | n/a | 1.1% | 24.7% |
Return vs Industry: Insufficient data to determine how BTTA.Y performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how BTTA.Y performed against the US Market.
Price Volatility
| BTTA.Y volatility | |
|---|---|
| BTTA.Y Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BTTA.Y has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BTTA.Y's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1946 | 2,074 | Michael Ramroth | www.biotest.com |
Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas.
Biotest Aktiengesellschaft Fundamentals Summary
| BTTA.Y fundamental statistics | |
|---|---|
| Market cap | US$1.51b |
| Earnings (TTM) | -US$64.53m |
| Revenue (TTM) | US$506.44m |
2.7x
P/S Ratio-21.0x
P/E RatioIs BTTA.Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BTTA.Y income statement (TTM) | |
|---|---|
| Revenue | €510.90m |
| Cost of Revenue | €429.10m |
| Gross Profit | €81.80m |
| Other Expenses | €146.90m |
| Earnings | -€65.10m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Nov 14, 2022
| Earnings per share (EPS) | -1.65 |
| Gross Margin | 16.01% |
| Net Profit Margin | -12.74% |
| Debt/Equity Ratio | 143.0% |
How did BTTA.Y perform over the long term?
See historical performance and comparison